

MarÃ-a-Victoria Mateos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8325272/publications.pdf>

Version: 2024-02-01

224
papers

28,674
citations

13099

68
h-index

5539

163
g-index

226
all docs

226
docs citations

226
times ranked

13982
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. <i>Blood</i> , 2022, 139, 492-501.	1.4	64
2	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	1.4	43
3	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.	5.2	19
4	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. <i>British Journal of Haematology</i> , 2022, 196, 639-648.	2.5	7
5	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	1.3	8
6	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 65-76.	10.7	80
7	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2598-2609.	7.0	14
8	Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial. <i>American Journal of Hematology</i> , 2022, 97, 481-490.	4.1	6
9	Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. <i>Lancet Haematology</i> , the, 2022, 9, e162-e165.	4.6	5
10	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , the, 2022, 9, e98-e110.	4.6	32
11	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3234-3239.	5.2	18
12	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. <i>Blood Cancer Journal</i> , 2022, 12, 32.	6.2	73
13	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	7.2	81
14	How I treat <sc>triple</sc> refractory multiple myeloma. <i>British Journal of Haematology</i> , 2022, 198, 244-256.	2.5	9
15	Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem cell transplantation is a prognostic marker of longer progression-free survival and overall survival. <i>British Journal of Haematology</i> , 2022, 198, 278-287.	2.5	6
16	Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	4.1	12
17	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.	6.2	8
18	Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma. <i>Advances in Hematology</i> , 2022, 2022, 1-7.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer Journal, 2022, 12, 76.	6.2	5
20	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematology, 2022, 9, e403-e414.	4.6	23
21	Moving Toward a Cure for Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 1-12.	3.8	2
22	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 2022, 40, 3406-3418.	1.6	115
23	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	1.4	512
24	Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2022, 387, 495-505.	27.0	291
25	Melflufen for the treatment of multiple myeloma. Expert Review of Clinical Pharmacology, 2022, 15, 371-382.	3.1	3
26	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3151-3161.	1.6	40
27	Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. Current Medical Research and Opinion, 2022, 38, 1759-1767.	1.9	5
28	Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. Leukemia, 2021, 35, 245-249.	7.2	10
29	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. British Journal of Haematology, 2021, 192, 522-530.	2.5	8
30	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood, 2021, 137, 49-60.	1.4	80
31	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	7.2	69
32	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia, 2021, 35, 1732-1744.	7.2	5
33	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 757-767.	1.6	98
34	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2021, 35, 31-44.	7.2	79
35	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 2021, 11, 40.	6.2	46
36	Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. British Journal of Haematology, 2021, 193, 561-569.	2.5	10

#	ARTICLE	IF	CITATIONS
37	Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. <i>Cancers</i> , 2021, 13, 1353.	3.7	22
38	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67
39	CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S433-S434.	1.2	1
40	Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. <i>Blood Advances</i> , 2021, 5, 1340-1343.	5.2	7
41	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
42	B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients. <i>Cancers</i> , 2021, 13, 1704.	3.7	6
43	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	17.0	11
44	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	6.2	14
45	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. <i>British Journal of Haematology</i> , 2021, 194, 784-788.	2.5	7
46	Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data. <i>Leukemia</i> , 2021, 35, 2924-2935.	7.2	21
47	Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. <i>American Journal of Hematology</i> , 2021, 96, 896-900.	4.1	12
48	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 785-798.	0.4	22
49	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 801-812.	10.7	162
50	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. <i>Blood</i> , 2021, 138, 1583-1589.	1.4	11
51	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	3.5	22
52	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. <i>Blood</i> , 2021, 138, 1901-1905.	1.4	23
53	Teclistamab, a B-cell maturation antigen-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. <i>Lancet</i> , The, 2021, 398, 665-674.	13.7	138
54	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.	3.7	11

#	ARTICLE	IF	CITATIONS
55	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	4.6	46
56	Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. <i>Blood</i> , 2021, 138, 157-157.	1.4	74
57	LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy. <i>Blood</i> , 2021, 138, 3057-3057.	1.4	1
58	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 896-896.	1.4	29
59	Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial. <i>Blood</i> , 2021, 138, 466-466.	1.4	19
60	Updated Phase 1 Results from MonumentAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 158-158.	1.4	38
61	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	6.2	62
62	CAR T-cells in patients with multiple myeloma. <i>Farmacia Hospitalaria</i> , 2021, 45, 219-220.	0.6	0
63	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. <i>Haematologica</i> , 2020, 105, 468-477.	3.5	41
64	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e30-e37.	0.4	75
65	The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. <i>Leukemia and Lymphoma</i> , 2020, 61, 680-690.	1.3	9
66	A matching-adjusted indirect treatment comparison (MAIC) of daratumumab+bortezomib+melphalan+prednisone (D-VMP) versus lenalidomide+dexamethasone continuous (Rd continuous), lenalidomide+dexamethasone 18 months (Rd 18), and melphalan+prednisone+thalidomide (MPT). <i>Leukemia and Lymphoma</i> , 2020, 61, 714-720.	1.3	3
67	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 509-518.	0.4	91
68	Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 132-141.	13.7	299
69	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 784-792.	1.6	175
70	Is there a role for new drugs with alkylating properties in multiple myeloma?. <i>Lancet Haematology</i> , 2020, 7, e357-e359.	4.6	2
71	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	6.2	126
72	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2020, 396, 186-197.	13.7	299

#	ARTICLE	IF	CITATIONS
73	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer Journal, 2020, 10, 108.	6.2	60
74	Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer Journal, 2020, 10, 103.	6.2	57
75	Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible. EJHaem, 2020, 1, 481-488.	1.0	0
76	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer Journal, 2020, 10, 91.	6.2	90
77	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. Cancers, 2020, 12, 3615.	3.7	7
78	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood, 2020, 136, 3033-3040.	1.4	146
79	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	13.7	188
80	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia, 2020, 34, 3007-3018.	7.2	26
81	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood, 2020, 136, 199-209.	1.4	76
82	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. Blood Cancer Journal, 2020, 10, 35.	6.2	16
83	Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review. BMC Cancer, 2020, 20, 170.	2.6	14
84	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of Hematology, 2020, 99, 1793-1804.	1.8	4
85	Measurable residual disease in multiple myeloma: ready for clinical practice?. Journal of Hematology and Oncology, 2020, 13, 82.	17.0	24
86	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. Blood Cancer Journal, 2020, 10, 14.	6.2	16
87	Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis. British Journal of Haematology, 2020, 189, 860-868.	2.5	3
88	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematology, the, 2020, 7, e370-e380.	4.6	170
89	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia, 2020, 34, 3019-3027.	7.2	17
90	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	1.3	3

#	ARTICLE	IF	CITATIONS
91	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	7.2	109
92	First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8500-8500.	1.6	40
93	Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8512-8512.	1.6	15
94	HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents. <i>Blood</i> , 2020, 136, 2-4.	1.4	4
95	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e459-e469.	4.6	174
96	Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. <i>Blood</i> , 2019, 134, 1337-1345.	1.4	148
97	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	1.8	39
98	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology</i> , 2019, 20, e302-e312.	10.7	290
99	Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. <i>British Journal of Haematology</i> , 2019, 186, e117-e121.	2.5	58
100	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. <i>Blood</i> , 2019, 133, 2664-2668.	1.4	11
101	Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. <i>Blood Cancer Journal</i> , 2019, 9, 38.	6.2	52
102	Improving the conditioning regimen in multiple myeloma. <i>Lancet Haematology</i> , 2019, 6, e234-e235.	4.6	0
103	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 23.	6.2	32
104	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. <i>Blood</i> , 2019, 134, 2218-2222.	1.4	66
105	Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e352-e353.	0.4	2
106	Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma. <i>Lancet Oncology</i> , 2019, 20, 5-6.	10.7	7
107	Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. <i>British Journal of Haematology</i> , 2019, 185, 981-984.	2.5	18
108	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , 2019, 393, 253-264.	13.7	187

#	ARTICLE	IF	CITATIONS
109	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. <i>Leukemia</i> , 2019, 33, 1256-1267.	7.2	20
110	First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. <i>Blood</i> , 2019, 134, 143-143.	1.4	127
111	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2019, 134, 781-781.	1.4	38
112	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 581-581.	1.4	14
113	Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8000-8000.	1.6	25
114	Outcomes of patients with t(11;14) multiple myeloma: An International Myeloma Working Group (IMWG) multicenter study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8015-8015.	1.6	3
115	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8040-8040.	1.6	1
116	Once-weekly (70 mg/m ²) versus twice-weekly (56 mg/m ²) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2019, 37, e19505-e19505.	1.6	0
117	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. <i>Leukemia</i> , 2018, 32, 2427-2434.	7.2	8
118	Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. <i>Hematological Oncology</i> , 2018, 36, 463-470.	1.7	15
119	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 121, 74-89.	4.4	28
120	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , 2018, 32, 2032-2036.	7.2	12
121	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2018, 378, 518-528.	27.0	747
122	Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2035-2043.	1.6	55
123	Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	3.5	225
124	Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. <i>PLoS ONE</i> , 2018, 13, e0203392.	2.5	18
125	Timing of treatment of smoldering myeloma: early treatment. <i>Blood Advances</i> , 2018, 2, 3045-3049.	5.2	9
126	Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 953-964.	10.7	169

#	ARTICLE	IF	CITATIONS
127	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.4	61
128	Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. <i>Journal of Hematology and Oncology</i> , 2018, 11, 49.	17.0	33
129	Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients. <i>European Journal of Internal Medicine</i> , 2018, 58, 57-63.	2.2	9
130	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2018, 5, e563-e598.	4.6	97
131	One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone. <i>Blood</i> , 2018, 132, 156-156.	1.4	20
132	Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. <i>Blood</i> , 2018, 132, 124-124.	1.4	41
133	Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison. <i>Blood</i> , 2018, 132, 3553-3553.	1.4	2
134	Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8013-8013.	1.6	6
135	A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8021-8021.	1.6	19
136	Health-related quality of life in patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: Results from the ALCYONE trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8042-8042.	1.6	4
137	Understanding the Cellular Origin and Pathogenic Transcriptional Programs in Multiple Myeloma (MM) and Light-Chain Amyloidosis (AL) through the Dissection of the Normal Plasma Cell (PC) Development. <i>Blood</i> , 2018, 132, 188-188.	1.4	0
138	Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. <i>Haematologica</i> , 2017, 102, 922-931.	3.5	34
139	Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 517-523.	0.2	0
140	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. <i>Haematologica</i> , 2017, 102, 2113-2124.	3.5	19
141	Multiple myeloma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17046.	30.5	812
142	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <sc>Eloquent</sc> follow-up and <i>post-hoc</i> analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	2.5	120
143	Tratamiento del mieloma múltiple asintomático: recomendaciones del Grupo Español de Mieloma. <i>Medicina Clínica</i> , 2017, 148, 517-523.	0.6	3
144	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 6602-6615.	7.0	25

#	ARTICLE	IF	CITATIONS
145	Smoldering Multiple Myeloma: Who and When to Treat. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 716-722.	0.4	13
146	Targeted therapy and maintenance in myeloma. British Medical Bulletin, 2017, 122, 163-178.	6.9	0
147	Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. Hematological Oncology, 2017, 35, 746-751.	1.7	22
148	Management of multiple myeloma in the newly diagnosed patient. Hematology American Society of Hematology Education Program, 2017, 2017, 498-507.	2.5	64
149	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology, 2017, 35, 2900-2910.	1.6	248
150	Myeloma in Elderly Patients: When Less Is More and More Is More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 575-585.	3.8	16
151	Safety and efficacy of daratumumab-based regimens in elderly (>75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.. Journal of Clinical Oncology, 2017, 35, 8033-8033.	1.6	3
152	Myeloma in Elderly Patients: When Less Is More and More Is More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 575-585.	3.8	20
153	A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2017, 35, TPS8055-TPS8055.	1.6	1
154	Lenalidomide plus dexamethasone versus observation in patients with high-risk smoldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1127-1136.	10.7	128
155	Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case. Clinical Case Reports (discontinued), 2016, 4, 1096-1100.	0.5	1
156	Elotuzumab for treating myeloma. Expert Opinion on Orphan Drugs, 2016, 4, 215-222.	0.8	0
157	Thromboprophylaxis in multiple myeloma patients treated with lenalidomide – A systematic review. Thrombosis Research, 2016, 141, 84-90.	1.7	36
158	Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood, 2016, 127, 420-425.	1.4	51
159	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood, 2016, 127, 1151-1162.	1.4	68
160	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 2016, 127, 2955-2962.	1.4	686
161	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood, 2016, 127, 3165-3174.	1.4	129
162	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood, 2016, 128, 1174-1180.	1.4	110

#	ARTICLE	IF	CITATIONS
163	MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer Treatment and Research, 2016, 169, 3-12.	0.5	39
164	Multiple myeloma: patient outcomes in real-world practice. British Journal of Haematology, 2016, 175, 252-264.	2.5	220
165	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 754-766.	27.0	1,246
166	Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood, 2016, 127, 3035-3039.	1.4	34
167	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
168	Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 2016, 175, 448-456.	2.5	39
169	Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Annals of Hematology, 2016, 95, 2033-2041.	1.8	27
170	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet, The, 2016, 387, 1551-1560.	13.7	724
171	Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leukemia Research Reports, 2015, 4, 64-69.	0.4	12
172	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood, 2015, 125, 2068-2074.	1.4	586
173	Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. Haematologica, 2015, 100, 1096-102.	3.5	19
174	Authors'™ Response. American Journal of Hematology, 2015, 90, 146-146.	4.1	0
175	Smoldering Multiple Myeloma: When to Observe and When to Treat?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e484-e492.	3.8	6
176	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2015, 373, 621-631.	27.0	1,139
177	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. American Journal of Hematology, 2015, 90, 314-319.	4.1	58
178	Management of asymptomatic myeloma patients. Expert Review of Hematology, 2015, 8, 19-27.	2.2	0
179	Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Reviews, 2015, 29, 387-403.	5.7	48
180	Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood, 2015, 126, 858-862.	1.4	50

#	ARTICLE	IF	CITATIONS
181	Smoldering multiple myeloma. Blood, 2015, 125, 3069-3075.	1.4	211
182	V. Smoldering multiple myeloma. Hematological Oncology, 2015, 33, 33-37.	1.7	6
183	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2015, 372, 142-152.	27.0	1,144
184	Initial treatment of transplant-ineligible patients in multiple myeloma. Expert Review of Hematology, 2014, 7, 67-77.	2.2	8
185	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	10.7	3,343
186	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood, 2014, 123, 4136-4142.	1.4	125
187	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood, 2014, 123, 3073-3079.	1.4	380
188	GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. Blood, 2014, 124, 1887-1893.	1.4	95
189	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica, 2014, 99, 1114-1122.	3.5	42
190	Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. Blood, 2014, 124, 178-178.	1.4	6
191	Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine, 2013, 369, 438-447.	27.0	449
192	New Approaches to Smoldering Myeloma. Current Hematologic Malignancy Reports, 2013, 8, 270-276.	2.3	17
193	Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma. Seminars in Oncology, 2013, 40, 618-633.	2.2	24
194	Treatment for High-Risk Smoldering Myeloma. New England Journal of Medicine, 2013, 369, 1762-1765.	27.0	60
195	Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM-PETHEMA study. British Journal of Haematology, 2013, 163, 581-589.	2.5	27
196	Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 448-455.	1.6	250
197	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica, 2013, 98, 980-987.	3.5	193
198	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica, 2013, 98, 79-86.	3.5	132

#	ARTICLE	IF	CITATIONS
199	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. <i>Blood</i> , 2012, 119, 687-691.	1.4	274
200	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood</i> , 2012, 120, 1589-1596.	1.4	429
201	How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events. <i>Leukemia Research</i> , 2012, 36, S35-S43.	0.8	17
202	Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. <i>Blood</i> , 2012, 120, 2581-2588.	1.4	148
203	Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1627-1633.	1.6	202
204	Subcutaneous bortezomib: a step towards optimised drug use. <i>Lancet Oncology</i> , The, 2011, 12, 410-411.	10.7	8
205	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. <i>Blood</i> , 2011, 118, 529-534.	1.4	183
206	Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. <i>Blood</i> , 2011, 118, 4547-4553.	1.4	53
207	Can multiple myeloma become a curable disease?. <i>Haematologica</i> , 2011, 96, 1246-1248.	3.5	72
208	Characterization of haematological parameters with bortezomib+melphalan+prednisone versus melphalan+prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. <i>British Journal of Haematology</i> , 2011, 153, 212-221.	2.5	13
209	Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. <i>Haematologica</i> , 2010, 95, 1913-1920.	3.5	101
210	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010, 116, 3743-3750.	1.4	101
211	<i>P53</i> deletion may drive the clinical evolution and treatment response in multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 359-361.	2.2	47
212	Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. <i>British Journal of Haematology</i> , 2010, 148, 110-114.	2.5	102
213	Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2010, 16, 3260-3269.	7.0	62
214	Management of treatment-related adverse events in patients with multiple myeloma. <i>Cancer Treatment Reviews</i> , 2010, 36, S24-S32.	7.7	60
215	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 934-941.	10.7	427
216	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6086-6093.	1.6	154

#	ARTICLE	IF	CITATIONS
217	Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. <i>Haematologica</i> , 2009, 94, 1599-1602.	3.5	92
218	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 5775-5782.	1.6	263
219	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. <i>New England Journal of Medicine</i> , 2008, 359, 906-917.	27.0	1,787
220	Role of bortezomib for the treatment of previously untreated multiple myeloma. <i>Expert Review of Hematology</i> , 2008, 1, 17-28.	2.2	3
221	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. <i>Blood</i> , 2008, 112, 4017-4023.	1.4	425
222	New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. <i>Blood</i> , 2007, 110, 2586-2592.	1.4	447
223	Two new 3'PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. , 2000, 27, 35-43.		19
224	Two new 3' PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2000, 27, 35-43.	2.8	3